COMMUNIQUÉS West-GlobeNewswire

Reviva to Present at the 36th Annual ROTH Conference
07/03/2024
CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Strainsforpains, Inc. Investors Update: Strainsforpains, Inc. Showing Strong Revenue Growth
07/03/2024
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- -- (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH) Strainsforpains, Inc. is pleased to announce the successful acquisition of a substantial $130,000 [...]
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
07/03/2024
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd [...]
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
07/03/2024
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in median overall survival [...]
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
07/03/2024
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, [...]
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
07/03/2024
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase [...]
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
07/03/2024
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic [...]
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
07/03/2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from [...]
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
07/03/2024
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
Manitoba Harvest Hemp Foods Introduces Protein-Rich Breakfast Staples With New Superseed Instant Oatmeal
07/03/2024
Global Hemp Food Leader, Manitoba Harvest, Launches New Superseed Instant Oatmeal in Three Delicious Flavors Packed with Plant-Based Protein, Fiber, and Omegas to Help Fuel Your Mornings NEW YORK and WINNIPEG, Manitoba [...]
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
07/03/2024
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for clinical development by [...]
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
07/03/2024
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H [...]
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
07/03/2024
Q4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, adjusted operating income of $ 3.3 million Strong operating cash flow enabled 2023 debt [...]
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07/03/2024
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $ [...]
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
07/03/2024
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2 study of Descartes- [...]
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07/03/2024
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 – – WTX-124 recommended dose for expansion (RDE), initiation of [...]
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
07/03/2024
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non- [...]
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $8 Million
07/03/2024
Up to $3.5 M in cash proceeds Up to $4.5 M in debts conversion Proceeds to be used to further expand production capacity BOUCHERVILLE, Québec, March 07, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC . (TSXV: LSL) (the [...]
Le groupe LSL Pharma annonce une combinaison de placements privés pour un produit brut total maximum de 8 millions $
07/03/2024
Jusqu’à 3,5 millions $ de produits en espèces Jusqu'à 4,5 millions $ en conversion de dettes Les produits du financement serviront à augmenter la capacité de production BOUCHERVILLE, Québec, 07 mars 2024 (GLOBE NEWSWIRE [...]

Pages